Julie Sue Moyers

Title: Julie Sue Moyers: Innovator in Glucagon Receptor Antagonists

Introduction

Julie Sue Moyers is a prominent inventor based in Indianapolis, IN (US). She has made significant contributions to the field of pharmaceuticals, particularly in the development of glucagon receptor antagonists. Her work is crucial for advancing treatments for metabolic disorders.

Latest Patents

Moyers holds a patent for "Glucagon receptor antagonists, preparation and therapeutic uses." This invention discloses novel compounds of Formula (I), or pharmaceutically acceptable salts thereof, which exhibit glucagon receptor antagonist or inverse agonist activity. The patent also outlines methods for preparing these compounds and pharmaceutical compositions that include them. These innovations are aimed at treating diabetic and other glucagon-related metabolic disorders.

Career Highlights

Julie Sue Moyers is associated with Eli Lilly and Company, a leading pharmaceutical firm known for its commitment to innovation in healthcare. Her work at the company has positioned her as a key player in the development of new therapeutic solutions.

Collaborations

Moyers has collaborated with notable colleagues, including Mark Donald Chappell and Scott Eugene Conner. These partnerships have enhanced her research and contributed to the success of her inventions.

Conclusion

Julie Sue Moyers is a trailblazer in the field of glucagon receptor antagonists, with a patent that holds promise for treating metabolic disorders. Her contributions to Eli Lilly and Company and her collaborations with esteemed colleagues underscore her impact on the pharmaceutical industry.